Premium
Review article: Helicobacter pylori and gastro‐oesophageal reflux disease
Author(s) -
DELANEY B.,
McCOLL K.
Publication year - 2005
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2005.02607.x
Subject(s) - helicobacter pylori , medicine , gastroenterology , gastro , reflux , proton pump inhibitor , disease , gastric acid , gastritis , spirillaceae , stomach
Summary Epidemiological studies demonstrate a negative association between Helicobacter pylori infection and gastro‐oesophageal reflux disease and its complications. This might represent a protective effect because of the tendency for H. pylori infection to lower gastric acid secretion with advancing age. However, studies of the effect of H. pylori eradication on gastro‐oesophageal reflux disease have failed to show any worsening of gastro‐oesophageal reflux disease symptoms. Several interactions between H. pylori and proton‐pump inhibitor therapy used to treat gastro‐oesophageal reflux disease need to be considered. Helicobacter pylori infection improves the control of gastric acidity by proton‐pump inhibitors and this produces a small advantage in clinical control of reflux disease. The infection prevents rebound acid hypersecretion occurring when proton‐pump inhibitor therapy is discontinued. However, concerns have been expressed that the body gastritis induced by proton‐pump inhibitor therapy in H. pylori ‐infected subjects might increase the risk of gastric cancer. At present, it is unclear whether H. pylori should be eradicated in gastro‐oesophageal reflux disease patients.